Details for Patent: 9,421,201

Title:	Treating pain in patients with hepatic impairment
Abstract:	An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product. The primary package and package insert are contained in an optional secondary package and the package insert does not contain a warning, a dosing instruction, or a dosing table specifically directed to patients suffering from mild, moderate or severe hepatic impairment, and preferably explicitly states that dosing adjustment is not required for mild or moderate hepatic impairment.
Inventor(s):	Hartman; Andrew (Belmont, CA), Rubino; Christopher M. (Williamsville, NY), Robinson; Cynthia Y. (Burlingame, CA)
Assignee:	Pemis Ireland Pain Limited (Dublin, IE)
Filing Date:	May 20, 2016
Application Number:	15/160,359
Claims:	1. A method of treating pain in a patient having mild or moderate hepatic impairment, the method comprising: administering to the patient having mild or moderate hepatic impairment an oral dosage unit having at least 15 mg of hydrocodone bitartrate as the only active ingredient, wherein the dosage unit comprises an extended release formulation of hydrocodone bitartrate and the dosage unit is administered on a twice-a-day basis. 2. The method of claim 1, wherein the patient has mild hepatic impairment. 3. The method of claim 1, wherein the patient has moderate hepatic impairment. 4. The method of claim 1, wherein the dosage unit comprises 15 to 60 mg of hydrocodone bitartrate. 5. The method of claim 1, wherein the dosage unit comprises 15, 30 or 60 mg of hydrocodone bitartrate. 6. The method of claim 1, wherein the dosage unit comprises 30 or 60 mg of hydrocodone bitartrate. 7. The method of claim 1, wherein the dosage unit provides a mean plasma half-life of hydrocodone of about 10 hours in patients with moderate hepatic impairment after a single administration of the dosage unit. 8. The method of claim 1, wherein the dosage unit provides a mean plasma half-life of hydrocodone of about 9.9.+-.2.1 hours in patients with moderate hepatic impairment after a single administration of the dosage unit. 9. The method of claim 1, wherein the dosage unit provides a mean time of maximum plasma concentration of about 6 hours in patients without hepatic impairment after a single administration of the dosage unit. 10. The method of claim 1, wherein the dosage unit provides a time of maximum plasma concentration of about 5 to about 7 hours in patients without hepatic impairment after a single administration of the dosage unit. 11. The method of claim 1, wherein the dosage unit provides a mean plasma half-life of hydrocodone of about 10 hours in patients with moderate hepatic impairment and provides a mean time of maximum plasma concentration of about 6 hours in patients without hepatic impairment after a single administration of the dosage unit. 12. The method of claim 1, wherein the dosage unit comprises hydroxypropyl methylcellulose. 13. The method of claim 1, wherein the dosage unit comprises particulates having a modified release coating comprising polymers. 14. A method of treating pain in a patient having mild or moderate hepatic impairment, the method comprising: administering to the patient having mild or moderate hepatic impairment an extended release oral dosage unit having at least 15 mg of hydrocodone bitartrate as the only active ingredient, wherein the dosage unit is administered on a twice-a-day basis and the dosage unit comprises particulates having a coating comprising one or more cellulose ethers. 15. The method of claim 14, wherein the dosage unit provides a mean plasma half-life of hydrocodone of about 10 hours in patients with moderate hepatic impairment after a single administration of the dosage unit. 16. The method of claim 14, wherein the dosage unit provides a mean time of maximum plasma concentration of about 6 hours in patients without hepatic impairment after a single administration of the dosage unit. 17. The method of claim 14, wherein the dosage unit comprises 15, 30 or 60 mg of hydrocodone bitartrate. 18. The method of claim 14, wherein the dosage unit comprises hydroxypropyl methylcellulose.